Salspera is a private, clinical stage company developing its platform of novel microbiome immunotherapies in solid tumor indications.
This innovative approach to immunotherapy has been shown to be safe and effective in human clinical trials and through years of published animal studies.
Salspera’s lead candidate, Saltikva®, is an oral immunotherapy that is currently in a Phase 2 study in patients with metastatic pancreatic cancer
Salspera is developing its novel bacterial-based immunotherapy platform in additional solid tumor indications
Saltzman DA, Augustin LB, Leonard AS, Mertensotto M, and Schottel J: Low Dose Chemotherapy Combined with Attenuated Salmonella Significantly Reduces Tumor Burden and is Less Toxic than High Dose Chemotherapy in an Autochthonous Murine Model of Breast Cancer. Surgery, 163(3):509-514, 2018. PMID 29229318
Drees JJ, Mertensotto MJ, Augustin LB, Schottel JK. Saltzman DA: Attenuated Salmonella Vascular Disruption Enhances Bacterial Targeting of Autochthonous Tumors, 2015 Journal of Cancer, 6(9):843-848. PMID 26284135
Eddie Moradian, Ph.D.
Salspera Co-founder and Chief Executive Officer
Dr. Moradian is the co-founder and Chief Executive Officer of Salspera. Founding of over two-dozen companies over a career spanning nearly 25 years in the healthcare, pharma and biotechnology industry, Dr. Moradian provides Salspera with the leadership and management experience needed to forge the path forward. Results- and metrics-oriented as well as process driven in management, he has created companies that have each garnered high respect in their industrial area, from customers, trade partners, as well as collaborators and competitors. This management experience will benefit Salspera in its effort to pursue value creation in the most efficient ways and with the participation of collaborators. Dr. Moradian received his Ph.D. in biotechnology in 1991 from the Swiss Federal Institute of Technology in Zurich, Switzerland and is a member of various leading industrial organizations.
Daniel Saltzman, M.D., Ph.D.
Salspera Co-founder and Chief Medical Officer
Dr. Saltzman is the co-founder and Chief Medical Officer of Salspera. Considered a renowned expert in the field of microbial immunotherapy, he has led an experimental therapeutic cancer immunotherapy laboratory for the last two decades. Specifically, he has studied the use of attenuated Salmonella as a tumor-targeted vehicle to carry immune modulating proteins directly to the tumor microenvironment. Dr. Saltzman is the Chief of Pediatric Surgery at the University of Minnesota Medical School/University of Minnesota Masonic Children’s Hospital. He holds the AS Leonard Endowed Chair in Pediatric Surgery. A native of the Panama Canal Zone, Dr. Saltzman obtained his B.S., M.D., and Ph.D. degrees from the University of Minnesota. He completed his surgical residency at the University of Minnesota and a Pediatric Surgery Fellowship at the University of Arkansas. Dr. Saltzman has authored over 130 articles (manuscripts and abstracts) published in the medical literature, has written 10 book chapters, and holds 5 patents. Dr. Saltzman is an examiner for the Pediatric Surgery Portion of the American Board of Surgery. He sits on the editorial board of the Journal of Surgical Education and is an ad hoc reviewer for the Journal of Pediatric Surgery and five other journals. In addition, he has an active clinical practice where Dr. Saltzman has expertise in Pediatric Cancers, Gastrointestinal Disorders, and Chest Wall Deformities. The Saltzman Research Lab is considered a world leader in the use of bacteria to deliver immunomodulatory proteins directly to cancers. He wrote the very first journal article ever published on the use of Salmonella for cancer therapy. His lab has developed a Salmonella based cancer treatment strategy that is currently in clinical human trials.
M. Chandler Glass
Business Development Manager
Chandler Glass is the Business Development Manager at Salspera. He joined Salspera in March 2020 and is responsible for leading the company’s business and corporate development, alliance management, and strategy functions across the company’s research and development portfolio. Prior to joining Salspera in 2020, he worked in corporate development at Eloxx Pharmaceuticals, a clinical stage biotechnology company developing treatments for rare and ultra-rare nonsense mutation mediated diseases. He received his B.S. in Biomedical Engineering from Tufts University.